Medicine and Dentistry
Antigen Specificity
12%
Antineoplastic Activity
20%
Arm
14%
Biological Marker
12%
Cancer Chemotherapy
20%
Cancer Immunization
20%
Cells
24%
Chemotherapeutic Agent
32%
Chemotherapy
63%
Cisplatin
36%
Combination Therapy
48%
Cross Presentation
20%
CTLA-4
14%
Cytoreductive Surgery
11%
Cytotoxic Chemotherapy
13%
Cytotoxic T-Cell
29%
Dendritic Cell
36%
Depletion
19%
Drive
12%
Drug
32%
Gemcitabine
15%
Immune Checkpoint Blockade
24%
Immune Response
12%
Immunotherapy
25%
Inpatient
11%
Interferon
12%
Introspection
12%
Malignant Neoplasm
34%
Mechanism of Action
17%
Mesothelioma
42%
Monocyte
12%
Neoplasm
100%
Nodular Melanoma
21%
Overall Survival
13%
Patient
54%
Pemetrexed
15%
Platinum
21%
Pleura Mesothelioma
22%
Surgery
22%
Survival
23%
Symptom
12%
T Cell
15%
T Lymphocyte Receptor
12%
Therapeutic Procedure
64%
Treatment Response
14%
Tumor Antigen
21%
Tumor Cell
18%
Tumor Immunity
21%
Tumor Microenvironment
29%
Tumor Model
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Alpha Interferon
10%
Antibody
5%
Biological Marker
15%
Cancer Chemotherapy
20%
Cancer Model
10%
Carboplatin
6%
Chemotherapy
39%
Cisplatin
30%
Clinical Study
6%
Clinical Trial
9%
Combination Therapy
6%
Cytotoxic Chemotherapy
5%
Cytotoxic T Lymphocyte Antigen 4
11%
Diseases
8%
DNA
6%
Drug
29%
Drug Combination
10%
Drug Discovery
10%
Durvalumab
20%
Immunotherapy
27%
Ligand
5%
Malignant Neoplasm
68%
Maximum Tolerated Dose
11%
Melanoma
10%
Mesothelioma
25%
Mouse
19%
Mouse Model
10%
Neoplasm
64%
Pemetrexed
8%
Peroxisome Proliferator Activated Receptor
10%
Platinum
21%
Pleura Mesothelioma
33%
Protein Tyrosine Kinase
10%
Sarcoma
5%
Sensitization
10%
Soft Tissue Sarcoma
10%
Transforming Growth Factor Beta
10%
Trastuzumab
10%
Tumor Microenvironment
25%
Tumor Necrosis Factor
10%
Wound Healing
5%
Immunology and Microbiology
Antigen
5%
Antigen Specificity
16%
Cells
11%
Cross-Presentation
10%
CTLA-4
15%
Cytotoxic T-Cell
8%
Dendritic Cell
20%
Dexamethasone
10%
Dose
6%
Dynamics
23%
Electric Potential
6%
Flow
7%
Immune Checkpoint Blockade
43%
Immune Response
6%
Immunity
72%
Immunotherapy
22%
Interferon Alfa
10%
Interferon Type I
16%
Lymphocyte
7%
Memory
10%
Molecule
5%
Monocyte
12%
Monospecific Antibody
5%
Mouse
23%
Murine
13%
Neoantigen
10%
Peripheral Blood Lymphocyte
13%
Pertuzumab
6%
Phenotype
9%
Programmed Death-Ligand 1
5%
Regulatory T Cell
12%
Sensitization
10%
STAT1
10%
Survival
8%
T Cell Receptor
20%
T-Helper Cell
15%
Trastuzumab
10%
Tumor Antigen
17%
Tumor Immunity
14%
Tumor Necrosis Factor Alpha
10%
Tumor-Associated Macrophage
12%
Volume
5%